LindaC.HoMD

Hematopathology, Anatomic Pathology, Clinical Pathology

Medical Director, Late Stage Clinical Development

Dr. Ho is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Case Western Reserve University/University Hospitals Cleveland Medical Center Surgical PathologyFellowship, Selective Pathology, 2009 - 2010
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematopathology, 2008 - 2009
McGaw Medical Center of Northwestern UniversityResidency, Pathology-Anatomic and Clinical, 2003 - 2008
Loyola University Chicago Stritch School of MedicineClass of 2003
Case Western Reserve University BA, Medical Anthropology and Biology, magna cum laude, 1994 - 1998

PubMed

109 citations
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren
Blood. 2021-08-12
16 citations
NRP-1/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in precursor B-cell acute lymphoblastic leukemia.
Howard J. Meyerson, Georgetta Blidaru, Alison Edinger, Ebenezer S. Osei, Karen Schweitzer
American Journal of Clinical Pathology. 2012-01-01

Abstracts/Posters

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above
Christopher A. Yasenchak, MD , Rodolfo Bordoni, MD , Victor Yazbeck, MD , Dipti Patel-Donnelly, MD , Timothy Larson, MD , Trevor Newhook, MS , Linda Ho , Matthew..., American Society of Hematology, Orlando, FL, 11/13/2019
Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years
Christopher A. Yasenchak, MD , Rodolfo Bordoni, MD , Victor Yazbeck, MD , Dipti Patel-Donnelly, MD , Thomas Anderson , Timothy Larson, MD , Trevor Newhook, MS , ..., American Society of Hematology, Orlando, FL, 11/13/2019
Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma
Judah Friedman, MD , Hun Ju Lee, MD , Linda Ho , Ian W. Flinn, MD PhD, American Society of Hematology, Orlando, FL, 11/13/2019